


WILEX


Focused Cancer Therapies



Company update

Jefferies 2011 Global Healthcare Conference
27 September 2011


- Oncology-focused biopharmaceutical company
- Transition from R&D to commercially driven business
- Product candidates with strong competitive profiles
- Important clinical and commercial milestones in the next months
- Integrative approach through combination of therapeutics and diagnostics



Therapeutics (Rx) + Diagnostics (Dx) + Customer Specific Research (Cx)

WILEX

Focused Cancer Therapies



REDECTANE[®]


(INN: 124I-girentuximab)

Radio-labelled antibody targeting CAIX for diagnostic use

REDECTANE®: First in class diagnostic imaging agent


- **Antibody Girentuximab radio-labelled with ¹²⁴I for diagnostic use**
 - Targets CA IX* antigen
 - Antigen abundantly expressed in clear cell Renal Cell Carcinoma (ccRCC), bladder, head & neck and colon cancers
- **High medical benefit**
 - could avoid surgery
- **Expected to be the first commercial product**
- **Peak sales potential > \$100m in ccRCC only**
- **Strong worldwide commercial partnership with Ion Beam Applications (IBA)**

* Carbonic Anhydrase IX
** PET-CT: Positron-Emission Tomography – Computerised Tomography,



REDECTANE®: Phase III trial PET/CT outperformed CT

→ Phase III trial of 226 patients with renal masses in 14 US sites




**SPA Special Protocol Assessment

Study endpoints	Specificity correct diagnosis that ccRCC is not present	Sensitivity correct diagnosis of ccRCC
REDECTANE® (PET-CT)	87%	86%
CT	47%	76%
REDECTANE® vs. CT	p<0.001	p≤0.016
REDECTANE® vs. arbitrary value of 75%	p=0.057	p≤0.002

→ **Next milestones:** Further discussion with FDA in preparation

WILEX

Focused Cancer Therapies



RENCAREX[®]

(INN: girentuximab)

CA IX targeting monoclonal antibody for therapeutic use

RENCAREX®: Therapy for adjuvant treatment of clear cell Renal Cell Carcinoma (ccRCC)

→ Chimeric monoclonal antibody for therapeutic use

- Targets CA IX antigen
- Abundantly expressed in ccRCC, bladder, head & neck and colon cancers
- Cell killing via validated mechanism of action (ADCC*)

→ High medical benefit

- Delay onset of metastatic disease


→ Three Phase II studies completed, total of 104 patients

- Metastatic Stage IV renal cell carcinoma patients
- Efficacy as monotherapy and in combination
- Safe and well tolerated

→ No drug approved by FDA / EMA in non-metastatic ccRCC

- Peak sales potential of ~ \$500m in ccRCC only


→ Marketing and co-development deals with Esteve for Southern Europe (2004) and Prometheus for the USA (2011)



* Antibody Dependant Cellular Cytotoxicity



→ Phase III trial with 864 patients with non-metastatic RCC in 142 sites worldwide




	Conducted at	Date	Outcome / Options
Interim analysis for futility	100 events DFS	12/2007	IDMC recommended "continue trial"
All patients enrolled	864 patients	07/2008	Treatment completed 6 months later, Follow-up CT-scans
Interim analysis for efficacy	343 events DFS	Start 01/2011	IDMC recommendation H2 /2011: "Consider filing", "Continue trial" or "Stop trial"
Final analysis	512 events DFS	-	

→ **Current status:** Interim analysis started in Q1 2011, IDMC recommendation H2 2011

WILEX

Focused Cancer Therapies



MESUPRON[®]
(INN: Upamostat)
Oral uPA inhibitor

MESUPRON®: First-in-class therapy targeting primary and metastatic tumour growth

- **MESUPRON® inhibits the Urokinase-type Plasminogen Activator (uPA) system**
 - Oral small molecule for novel non-cytotoxic, anti-metastatic approach in cancer therapy
 - To specifically block tumour metastasis in solid cancers
- **uPA level a predictor of survival**
 - Hypothesis that inhibiting uPA should therefore increase survival
- **World leader in uPA inhibitors:**
 - Strong IP position and high entry barrier
- **Extensive Ph I programme to determine safety, tolerance and Ph II dose rationale**
- **Peak sales potential of ~ \$ 1 bn for various indications**
- **Worldwide partnership planned**




MESUPRON®: Phase II pancreatic cancer trial

Encouraging clinical proof of concept data

→ Phase II trial of 95 pancreatic cancer patients

→ 30 centres in 6 European countries, completed in June 2010



Final data	Gemcitabine alone	Gemcitabine & MESUPRON® (200 mg)	Gemcitabine & MESUPRON® (400 mg)	Improvement***
Tumour response*	15.4%	21.4%	35.5%	doubled
PFS rate at 12 months	16.2%	22.5%	26.9%	66%
Median OS (months)	9.9	9.7	12.5	26%
1 year survival	33.9%	40.7%	50.6%	49%


* Partial response (All CTs were assessed by central independent radiology. Responses were assessed from Waterfall plots using RECIST cut-off criteria.)

** Poplin et al JCO Aug 2009: 9.2 months for Gemcitabine

*** Improvement between Gemcitabine alone and Gemcitabine & MESUPRON 400mg
PFS /progression free survival , OS / overall survival


→ Phase II trial of 132 breast cancer patients ongoing

- First line therapy for HER-2 receptor negative, metastatic breast cancer
- Combination therapy with Capecitabine (Xeloda®), double-blind design
- 20 centres in Belgium, Brazil, Germany, Israel, USA
- Patient recruitment started in August 2008 and completed in May 2011



→ Next milestones

- Study data (PFS) expected during 2012



WX-554 (MEK inhibitor)


WX-037 (PI3K inhibitor)

→ **WX-554 oral small molecule MEK inhibitor**

- Mitogen-activated protein kinase (MEK) plays a central role in signal transduction
- MEK signalling pathway is over expressed in more than 30% of cancers, resulting in increased tumour growth and proliferation
- Data of first Phase I, i.v. administered in healthy volunteers published in Q2 2010
- Oral Phase I in healthy volunteers started in Q2 2011
- Further oral Phase I in cancer patients planned for 2012

→ **WX-037 oral small molecule PI3K inhibitor**



- Phosphatidylinositol-3-kinase/protein kinase (PI3K) signalling pathway sends a “growth” signal to the nucleus of a tumour cell
- Inhibition of the PI3K signalling pathway is of great therapeutic interest
- Development candidate selected and preclinical development underway
 - GMP (good manufacturing practice) synthesis development started
 - First toxicity studies of WX-037 completed



Products & Technologies

Heidelberg Pharma at a glance

Profile	→ Focused on novel cancer therapies
Business Model	→ ADC technology platform business → Preclinical contract research business (CSR)
Capabilities	→ Proprietary antibody drug technology → Preclinical: Bioanalytics, Cell Biology, Pharmacology
Organisation	→ Located in Ladenburg, Germany → 41 Employees (32 FTE)
Financials	→ Revenues through preclinical client specific contract research business
Terms	→ Share deal: 3.2 m WILEX shares at €6 per WX share for 100% of Heidelberg Pharma completed in 03/2011



- **Mode of action:** The antibody guides the toxin high selectively to the tumour cell, the linker provides cleavage and release of the toxin within the targeted tumour cell ONLY, the toxin kills the tumour cell
- Combining specificity & efficacy
- Proof of concept in vivo tumour model showed impressive results

Profile	<ul style="list-style-type: none">→ Former Companion diagnostics business unit of Siemens Healthcare→ Strategic IP and commercial products in Companion diagnostics
Business Model	<ul style="list-style-type: none">→ Manufacturing and commercialisation of oncology biomarker assays→ Biomarker diagnostics (ELISA and IHC): HER2, CA IX, uPA, PAI-1, EGFr, TIMP
Capabilities	<ul style="list-style-type: none">→ GMP manufacturing facility→ State of the art facilities and equipment
Organisation	<ul style="list-style-type: none">→ Located in Cambridge, MA/USA→ 11 Employees (10 FTE)
Financials	<ul style="list-style-type: none">→ Cash flows from product sales
Terms	<ul style="list-style-type: none">→ Acquisition of core assets (inventory, equipment) for € 426 k in 2010→ Low single digit royalties to Siemens

Positioning

- IP and biomarker tests to provide tools for targeted therapies




Advantages

- Measuring proteins in blood with ELISA tests
- Bioanalytical methods designed to select patients for therapy
- Assessment how patients will respond to a specific medical treatment
- Monitoring of patient's treatment and outcome

WILEX

Focused Cancer Therapies



**Deals and alliances –
Strong partners**



- **WILEX acquired UCB's entire preclinical oncology portfolio in 2009**
 - Worldwide licence rights for 2 small molecule and 3 antibody programmes
 - €20m in equity and milestone payments received
- **Joint development strategy includes buyback options for UCB**
- **WX-554 oral small molecule MEK inhibitor**
 - Phase I clinical development started in Q4 2009
 - 2 milestone payments of € 5m each received
- **WX-037 oral small molecule PI3K inhibitor**
 - Development candidate selected and preclinical development underway
- **2 antibody programmes progressing in research**

REDECTANE®



→ Commercialisation agreement with Ion Beam Applications

- Signed in June 2008
- WILEX responsible for antibody manufacture and clinical development
- IBA responsible for manufacturing of finished radio-labelled antibody, distribution, sales & marketing
- Worldwide co-promotion rights for WILEX
- WILEX received upfront payment, receives development milestones and royalties up to 45% on ex-factory sales

RENCAREX®

→ Marketing and co-development deal with Esteve

- Signed 2004
- Southern Europe (Spain, Italy, Greece, Portugal, Andorra)



RENCAREX[®]

- **Exclusive US commercialisation deal with Prometheus Laboratories**
 - Signed in April 2011
- **WILEX receives from Prometheus**
 - \$39 million in cash:
 - \$19 million upon signing **AND**
 - either \$20 million after twelve months or European commercial rights to an undisclosed product **AND**
 - Milestones and co-funding for the ongoing development of RENCAREX[®] **AND**
 - Royalties on US net sales of RENCAREX[®]
 - RCC and potential development in further indications
- **Deal valued at > \$145 million in cash for upfront, milestone payments and reimbursed costs plus royalties for US only**



**Strategic focus: Transition from R&D
to commercially driven business**

→ Commercialisation rights to a undisclosed approved and marketed drug

- provides the opportunity for WILEX to consider the creation of an own highly-specialised European sales & marketing organisation


→ Sales & marketing strategy for RENCAREX®

- USA: Prometheus
- Southern Europe: Esteve
- Rest of Europe: WILEX and sales partners
- Rest of World: Enter into alliance with distributors and sales partners


→ Sales & marketing strategy for REDECTANE®

- IBA: worldwide
- WILEX: Co-Promotion rights worldwide







- Focussed on target and indication with various mode of actions for personalised cancer treatment
- CA IX as an example for an integrative approach through combination of therapeutics and diagnostics




→ Realisation of the commercialisation strategy




Broad portfolio and strong partners

Product	Technology	Indication	Research	Pre-clinical	Clinical development			Market	Partner	
					Phase I	Phase II	Phase III			
REDECTANE®	Antibody (diagnostic)	Renal mass	→						 (ww**)	
RENCAREX®	Antibody (therapeutic)	non-metast. ccRCC*	→						 (Southern Europe)  PROMETHEUS® (USA) Therapeutics & Diagnostics	
MESUPRON®	uPA inhibitor	Pancreatic cancer	→							
		Breast cancer	→							
WX-554	MEK inhibitor	Cancer	→						 (ww)	
WX-037	MEK inhibitor	Cancer	→						 (ww)	
2 Antibodies		Cancer	→						 (ww)	
ADC Platform	Antibody drug conjugates	Cancer	→						WILEX Group	
Diagnostic tests	ELISA/IHC	HER-2, CAIX, uPA, PAI-1, EGFr; VEGF etc.	→							WILEX Group

*clear cell Renal Cell Carcinoma, non-metastatic, ** worldwide



Achievements and Outlook



- ✓ Start process for interim analysis for efficacy
- ✓ US commercialisation rights to Prometheus Laboratories Inc.
- ✓ Patient recruitment Phase II breast cancer trial completed
- ✓ Start oral Phase I in healthy volunteers



- ✓ Pre-BLA Meeting with the FDA in second quarter 2011
- ✓ ISO certification
- ✓ Changeover of product range to WILEX Inc.



- ✓ Integration of Heidelberg Pharma into the Group started
- ✓ Material Transfer Agreements with third companies for ADC


Rx	RENCAREX®	→ Interim analysis for efficacy, IDMC recommendation H2 2011 → Prometheus agreement: Decision product or \$20m cash
	MESUPRON®	→ Data expected 2012
	WX-554	→ Data oral Phase I in healthy volunteers expected Q1 2012 → Start oral Phase I in cancer patients expected early 2012
Dx	REDECTANE®	→ Further discussions with Medical Advisory Board and FDA
	In-vitro diagnostics	→ Expand customer base, increase sales
Cx	ADC + CSR	→ Third-party ADC collaborations → Increase sales revenue

In € m	Results 2010	Guidance 2011
Sales revenue & other income	1.3	9.0 – 11.0
Operating expenses	24.4	26.0 – 30.0
Operating result	(23.1)	(16.0) – (20.0)
Total funding requirement	25.5	24.0 – 27.5
Funds required per month	2.06	2.0 – 2.3
Employees	80	119

→ Improved guidance for 2011

→ Guidance comprises WILEX AG, WILEX Inc. and Heidelberg Pharma AG

→ Shareholder structure



* dievini Hopp BioTech holding GmbH & Co. KG +
Verwaltungsgesellschaft des Golf Club St. Leon-Rot mbH

→ Capital raised

- €68m private funding
- €55m IPO in 11/2006
- €10m UCB transaction in 02/2009
- €18.5m capital increases in 2009/2010
- €10m shareholder loan in 12/2010


→ Stock Exchange data

- FSE Prime Standard (Ticker symbol: WL6)
- 21,613,035 shares registered (€1.00/per share)

→ Financial calendar 2011

- 13 Oct. 9-month Financial Report

- Oncology-focused biopharmaceutical company
- Broad portfolio and strong partners
- Product candidates with strong competitive profiles
- Important clinical and commercial milestones in the next months
- Integrative approach through combination of therapeutics and diagnostics
- Transition from R&D to commercially driven business



Therapeutics (Rx) + Diagnostics (Dx) + Customer Specific Research (Cx)

For your notes

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of WILEX AG. This material may not be distributed within countries where it may violate applicable law.

WILEX AG

Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-0
Fax: +49 (0)89-41 31 38-99
Website: www.wilex.com

Corporate Communications

Katja Arnold (CIRO)
Email: investors@wilex.com
Tel.: +49 (0)89-41 31 38-126

ISIN: DE0006614720
Symbol: WL6
Reuters: WL6G.DE
Bloomberg: WL6G.GR